Arnaub Chatterjee, Datavant president and GM of life sciences, says the company will streamline data linking and evidence generation across real-world and clinical trial data.

The funds will be used to increase the development of GAIA-based Alzheimer's Disease drugs and widen the pipeline of blockbuster drug candidates.

The company will use the funds to move into the female health space and increase screening and preventive care.

The news comes alongside the U.S. Department of Defense’s announcement of $200 million contracts awarded to xAI, Anthropic, Google and OpenAI for AI implementation.